Neurology and Immuno-inflammation

Created in 2013 to capitalize on decades of expertise of drug developments in CNS, inflammation, and oncology at Cephalon laboratories (TEVA group), CleveXel Pharma is a biotech company specializing in innovative treatments for neurodegenerative diseases.

CleveXel Pharma is currently developing a risk-balanced portfolio of four drug projects ranging from lead optimization to clinical proof-of-concept. CleveXel objective is to manage a portfolio of 4 projects ranging from lead optimization to clinical proof-of-concept and has already established co-development and out-licensing agreements.

CleveXel’s is willing to open to partnership, licensing or capitalistic investment to speed-up and secure the advancement of the project. This applies to any of our projects, including CVXL-0074 for human indications.